Abstract

Rosacea involves elevated cathelicidin LL-37, generated by kallikrein-related peptidase 5, together with a neurogenic axis in which Substance P drives CREB-dependent transcriptional amplification. Disulfiram and its dithiocarbamate metabolite engage three mechanisms relevant to this pathology: metal-potentiated inhibition of ATF/CREB DNA binding; zinc-chelating inhibition of matrix metalloproteinase-9, which reduces kallikrein activity and LL-37 generation indirectly; and chelation of cutaneous zinc and copper, which may disinhibit kallikreins and raise reactive oxygen species, acting against the first two. This document discloses the resulting treatment method in full, including a representative regimen of 200 to 250 mg disulfiram with 1 to 2 mg elemental copper daily, and enumerates the agents, doses, ratios, metal cofactors, schedules, routes and indications covered. No controlled experiment has been performed. The choice of metal cofactor is unresolved and disclosed as an open parameter, since copper and zinc have opposite effects on two of the three mechanisms. The document states its predictions in advance, sets out inexpensive protocols that would falsify them, and is published to place the method in the public domain and invite testing.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS